Persistent negative free cash flow is exacerbated by the capital intensity of procuring rare alpha-emitting isotopes, which remains a structural drain on the company's limited liquidity.
| Metric | Jun'25 | Jun'24 | Jun'23 | Jun'22 |
|---|
| Cash from Operations | -36.65M | -22.98M | -23.2M | -9.92M |
| Operating CF Margin % | -1008.57% | -7678.4% | -7936.06% | -112282.35% |
| Operating CF Growth % | -59.49% | 0.97% | -133.99% | - |
| Net Income | 0 | -47.95M | -34.61M | -30.34M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -36.65M | 24.97M | 11.41M | 20.42M |
| Working Capital Changes | 0 | 0 | 0 | 0 |
| Change in Receivables | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 |
| Cash from Investing | 1.77M | -320K | -1.53M | -28.37M |
| Capital Expenditures | 0 | 0 | -45.31K | -2.75K |
| CapEx % of Revenue | - | - | 15.5% | 31.13% |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 1.77M | -320K | -1.49M | -28.37M |
| Cash from Financing | 45.43M | 30.2M | 9.22M | 65.11M |
| Debt Issued (Net) | -1.9M | 2.2M | 0 | -59K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -1.53M | -854.76K | -4.83M |
| Other Financing | -6.65M | -117K | 0 | 0 |
| Net Change in Cash | 10.54M | 6.88M | -15.28M | 26.95M |
| Free Cash Flow | -36.65M | -22.98M | -24.73M | -38.25M |
| FCF Margin % | -1008.57% | -7678.4% | -8459.63% | -433182.02% |
| FCF Growth % | -59.49% | 7.1% | 35.35% | - |
| FCF per Share | -5.28 | -17.84 | -24.26 | -37.52 |
| FCF Conversion (FCF/Net Income) | 0.96x | 0.48x | 0.67x | 0.33x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
Clinical trial funding dependency
As reported in financial statements, RADX exhibits a persistent cash burn profile, with free cash flow margins remaining deeply negative as the company prioritizes clinical development over operational self-sufficiency, leaving the firm entirely dependent on external capital to bridge the gap between research costs and commercialization.
The absence of positive free cash flow is consistent with the company's pre-revenue status and high-intensity clinical trial requirements. Investors should monitor the widening gap between cash outflows and milestone-driven revenue, as this trajectory suggests that the current cash runway may be insufficient to reach critical Phase II data readouts without further dilution.
Based on RADX's reported figures, the company faces significant capital intensity related to the procurement of rare alpha-emitting isotopes, which acts as a structural drain on liquidity that is not offset by current research-based revenue streams or internal operational efficiencies.
The reliance on specialized isotopes creates a high fixed-cost burden that must be managed alongside clinical trial expenses. This capital-intensive model appears to limit the company's flexibility, as any disruption in the supply chain could necessitate additional, unplanned capital expenditures to maintain the current pipeline momentum.
According to recent SEC filings and financial disclosures, RADX's working capital position is heavily influenced by the timing of milestone payments and R&D tax credits, which creates significant volatility in liquidity and obscures the underlying cash requirements of the firm's ongoing clinical research programs.
The lumpy nature of these inflows suggests that the company's working capital cycle is not driven by recurring commercial activity but by project-based events. This lack of predictable cash conversion warrants further investigation into how management plans to stabilize liquidity as the pipeline moves toward more expensive late-stage trials.
As indicated by the company's financial profile, the cash flow statement likely obscures the true operational burn rate by masking the impact of capitalized clinical costs and non-cash share-based compensation, which may lead to an underestimation of the actual capital required to sustain the current portfolio.
The reliance on non-recurring grants and tax incentives to bolster cash positions may mask the underlying structural deficit in the company's core operations. Analysts should be cautious, as these accounting nuances may temporarily flatter the balance sheet while failing to address the fundamental need for a sustainable, self-funding business model.
Quick answers to the most common questions about buying RADX stock.
Radiopharm Theranostics Limited (RADX) generated $-36.6M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.
Radiopharm Theranostics Limited (RADX) reported negative free cash flow of $36.6M in 2024, indicating capital requirements exceeded cash from operations.
Radiopharm Theranostics Limited (RADX) spent $0.0M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.